1. NAT testing in Poland E. Brojer, M. Łętowska, A
NAT testing in Poland E. Brojer, M. Łętowska, A. Gronowska Institute of Hematology and Blood Transfusion, Warsaw, Poland
Introduction of NAT
HCV in plasma for fractionation March 2000
HCV in all donations - Jan 2002
Population: 38.5 mln
Reg. Blood Transf. Centers: 21
Donations: 1mln/year

2. Cobas AmpliScreen Roche
NAT Test format
BALTIC SEA
LITHUANIA
RUSSIA
BELARUS
UKRAINE
SLOVAKIA
CZECH REP.
Słupsk
Olsztyn
Zielona Góra
Wałbrzych
Wrocław
Łódź
Kraków
Radom
Kielce
Katowice
Opole
Szczecin
Lublin
Gdańsk
Bydgoszcz
Białystok
Poznań
Kalisz
Racibórz
Rzeszów
Warszawa
GERMANY
Cobas AmpliScreen Roche
plasma pools, 48 donations
8 Labs in RBT Centers
TMA HIV/HCV Chiron
single donations
2 Labs in RBT Centers
HCVcoreAg used supplementarily, (mainly in emergency)
Reference Lab (IHBT, Warsaw)
certification for all NAT Laboratories

3. Frequency of HCV positive „window period” donations
Plasma pool testing: / 1.80 mln
HCVcore Ag: / 0.34 mln
Single donation HIV/HCV : 0/ 0.39 mln
Overall frequency 44/ 2.5 mln
Elevated ALT in 30% of HCV RNA positive donors

4. RNAHCV(+) /anti-HCV (-)
Follow up and look back studies of HCV RNA positive/anti- HCV negative donors
Anti-HCV-/RNA HCV+
Anti-HCV+/RNA HCV+
Anti-HCV+/RNA HCV-
Anti-HCV-/RNA HCV- 7 14 1 2 3 4 5 6 8 9 10 11 12 13 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 33
anti-HCV detected in all donors, observed for more than 3 months
HCV RNA was not detected in 2/35 (6 and 20 months after eroconversion) 11 8 3 31
RNAHCV(+) /anti-HCV (-)
months

5. HCV genotype frequency in HCV RNA(+)/antiHCV(-) blood donors (%)

6. Viral load in HCV RNA positive/anti-HCV negative blood donors
4.2 x107
3.2x103